ClinicalTrials.gg
CompletedNCT00421109Updated Apr 5, 2012

Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

A Phase 3 interventional study of Bilastine and Levocetirizine in Urticaria, sponsored by Faes Farma, S.A.. Completed at 50 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-04-05.

Sponsored by Faes Farma, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
522
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.

Read the detailed description

A total of 540 patients with CIU will be enrolled in this pivotal, randomised, multicentre, international, double-blind, placebo and active-comparator controlled, parallel study . Patients will be selected from both public and private clinical practices. The study population includes males and females between 18 and 70 years of age, suffering from CIU for at least 6 weeks prior to entry in the study with no identifiable cause.

02

Conditions studied

  • Urticaria

Keywords

  • Urticaria
  • Hives
  • Wheals
  • Flare
  • Chronic
  • Idiopathic
  • Erythema
  • Skin diseases, vascular
  • Hypersensitivity, Immediate
  • Allergic
  • Cutaneous
03

In context

Urticaria

148 studies on the registry are indexed under Urticaria; 20 are open to participants now.

This study's enrollment of 522 is above the median of 51 across 104 interventional studies indexed under Urticaria.

Browse Urticaria studies →

Lead sponsor

Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years old.
  • Documented history of CIU for at least 6 weeks prior to entry in the study.

Exclusion criteria

Exclusion Criteria:

  • Dermatological pathology other than chronic idiopathic urticaria.
  • History of disorders, Hodgkin's disease, lymphoma, leukemia and generalized cancer.
  • Pregnant or breast-feeding women.
  • Patients who will be operating heavy machinery or need to drive motor vehicles as an essential part of their profession.
  • Patients who have a recent history (within previous 12 months) of drug addiction or alcohol abuse.
  • Patients who are currently participating in or have participated in another clinical trial within the last 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
522 participants (actual)

Study arms

  • Experimental
    1

    Bilastine 20 mg

    Drug: Bilastine

  • Active comparator
    2

    Levocetirizine 5 mg

    Drug: Levocetirizine

  • Placebo comparator
    3

    Placebo

    Drug: Placebo

Interventions

  • Encapsulated 20 mg Tablet. Once daily for 28 days

  • Encapsulated 5 mg tablet. Once daily for 28 days

    Also known as: Xyzall

  • DrugPlacebo

    Encapsulated tablet. Once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Change from baseline, in the am/pm Total Symptom Score (TSS3), over the 28 days of the treatment period according to the patient's assessment in the diary card. (Reflective Symptoms)

    Time frame: 28 days

Secondary outcomes

  1. Reflective and Instantaneous symptoms scores.

    Time frame: 28 days

  2. QoL questionnaire.

    Time frame: 28 days

  3. Overall assessment of discomfort caused by CIU.

    Time frame: 28 days

  4. Investigator's overall clinical impression.

    Time frame: End of study

  5. Assessment of the Impact of urticaria on the sleep scale.

    Time frame: 28 days

07

Study locations

50 sites
  • Centre nº 101
    Buenos Aires, 1035, Argentina
  • Centre nº 105
    Buenos Aires, 1280, Argentina
  • Centre nº 104
    Buenos Aires, 1406, Argentina
  • Centre nº 103
    Buenos Aires, 1425, Argentina
  • Centre nº 107
    Buenos Aires, 1425, Argentina
  • Centre nº 109
    Buenos Aires, 1425, Argentina
  • Centre nº 108
    Buenos Aires, 6500, Argentina
  • Centre nº 100
    Mar Del Plata / Buenos Aires, 7600, Argentina
  • Centre nº 106
    Rosario - Santa Fe, 2000, Argentina
  • Centre nº 102
    Salta, 4400, Argentina
  • Centre nº 202
    Aalst, 3300, Belgium
  • Centre nº 200
    Edegem, 2650, Belgium
  • Centre nº 201
    Gent, 3000, Belgium
  • Centre nº 204
    Gent, 3000, Belgium
  • Centre nº 203
    Kortrijk, 8500, Belgium
  • Centre nº 302
    Lyon, 69003, France
  • Centre nº 305
    Marseille cedex 9, 13274, France
  • Centre nº 307
    Nice cedex 3, 06202, France
  • Centre nº 303
    Paris cedex 10, 75475, France
  • Centre nº 308
    Quimper, 29000, France
  • Centre nº 301
    Reims, 51092, France
  • Centre nº 411
    Berlin, 12353, Germany
  • Centre nº 404
    Berlin, 13055, Germany
  • Centre nº 410
    Berlin, 13439, Germany
  • Centre nº 400
    Hamburg, 20354, Germany
  • Centre nº 407
    Hannover, 30159, Germany
  • Centre nº 406
    Leipzig, 4103, Germany
  • Centre nº 505
    Iwonicz Zdroj, 38-440, Poland
  • Centre nº 507
    Krakow, 31-462, Poland
  • Centre nº 503
    Krakow, 31-908, Poland
  • Centre nº 504
    Lodz, 91-347, Poland
  • Centre nº 502
    Lublin, 20-080, Poland
  • Centre nº 506
    Poznan, 60-631, Poland
  • Centre nº 501
    Warszawa, 00-891, Poland
  • Centre nº 500
    Wroclaw, 50-044, Poland
  • Centre nº 704
    Brasov, 500414, Romania
  • Centre nº 700
    Bucharest, 040213, Romania
  • Centre nº 701
    Bucharest, Romania
  • Centre nº 702
    Bucharest, Romania
  • Centre nº 705
    Bucharest, Romania
  • Centre nº 706
    Bucharest, Romania
  • Centre nº 707
    Bucharest, Romania
  • Centre nº 703
    Craiova Dolj, Romania
  • Centre nº 804
    Vitoria, Alava 01004, Spain
  • Centre nº 802
    Badalona, Barcelona 08916, Spain
  • Centre nº 801
    Leganes, Madrid 28911, Spain
  • Centre nº 803
    Bilbao, Vizcaya 48013, Spain
  • Centre nº 805
    Barcelona, 08036, Spain
  • Centre nº 800
    Madrid, 28004, Spain
  • Centre nº 806
    Valencia, 46009, Spain
08

References and documents

Publications

  • Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011 Sep;10(5):779-93. doi: 10.1517/14740338.2011.604029. Epub 2011 Aug 11. Erratum In: Expert Opin Drug Saf. 2012 Jan;11(1):175. PubMed 21831011 ↗
  • Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antepara I, Jauregui I, Valiente R; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010 Apr;65(4):516-28. doi: 10.1111/j.1398-9995.2009.02217.x. Epub 2009 Oct 23. PubMed 19860762 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2007
First posted
Jan 11, 2007
Start
Jul 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Apr 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00421109
Lead sponsor
Faes Farma, S.A.
Responsible party
Sponsor
First posted
Jan 11, 2007
Start date
Jul 2006
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Apr 5, 2012

Study contacts

OLMOS, MD
principal investigator · HOSP CLINICO SAN CARLOS, SERVICIO DERMATOLOGIA (Madrid- Spain)
DE WEERT, MD
principal investigator · UZ GENT/ DE PINTELAAN 185 (Belgium)
DUBERTRET, MD
principal investigator · HOPITAL ST LOUIS/SCE DERMATOLOGIE/1 AV. CLAUDE VELLEFAUX (Paris- France)
SIMON, MD
principal investigator · UNIV. KLINIKUM LEIPZIG/KLINIK FÜR DERMATOLOGIE (Germany)
KAPINSKA-MROWIECKA, MD
principal investigator · SZPITAL SPECJALISTYCZNY IM.S. ZEROMSKIEGO/ODDZIAL DERMATOLOGII/ OS. MLODOSCI 11 (Krakow- Poland)
BENEA, MD
principal investigator · Spit Clin Dermato-Venero."Prof.Dr./Scarlat Longhin"/Calea Serban Voda216,sector4 (Bucharest- Romania)
HERRERO, MD
principal investigator · CONSULTORIO DE ALERGIA 1° PISO/HOSPITAL JUAN A. FERNANDEZ/CERVINO 3355 (Buenos Aires- Argentina)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilastine

Start the discussion